Financial PositionThe company ended the quarter with $36.2 million in cash, which management believes provides runway to fund ongoing operations until 4Q25.
Oncology Program TerminationThe company announced a strategic refocus for icovamenib exclusively centered on metabolic disorders and terminated all ongoing oncology trials for the menin inhibitor candidate.
Organizational ChangesThe company underwent a workforce reduction of approximately 35%, and consolidated all operations at a single facility.